Captek Softgel International acquires J+D Labs
J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations complements Captek’s offerings.
California-based Captek Softgel International (CSI) has acquired J+D Labs Pharma Manufacturing. CSI is a portfolio company of Swander Pace Capital (SPC), and the acquisition of J+D Labs is a continuation of SPC’s focus on investing in and growing industry-leading vitamin, mineral, and supplement companies.
For decades J+D Labs has been well recognized in the nutraceutical industry as a first-class manufacturer of health and wellness supplements producing more than 1,000 unique formulations. More recently J+D Labs has brought NutraStock to the market, more than 250 bulk stock dietary supplements manufactured in the US.
Captek CEO David Wood said this union will result in a greater diversity of offerings and services within the supplement channel. “We have long regarded J+D Labs’ reputation and the significance of what they bring to the table as a leader in the industry,” he said. J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations was a perfect complement to Captek’s offerings. Wood stated, “Going forward, we are committed to our collective success through focusing on our customers, sharing best practices, and continuing our best-in-class quality and compliance standards.”
“This acquisition is positive for everyone: for our employees, our suppliers, our customers, and the end-users,” said J+D Labs owner, Jay Majmudar. CSI is well established in more than 20 countries. “We are happy to play a key role in helping to expand distribution even further. We will continue to make quality, price, and timely delivery a top priority,” emphasized Majmudar.
The newly joined companies will continue to produce high quality products in both Cerritos and Vista, CA. This will give customers the business continuity planning they have long sought by having the ability to have their products manufactured at either site. As a result, more than 300,000 sq ft of manufacturing, warehousing, and analytical testing labs will immediately bring to market greater capacity, expertise, comprehensive turnkey packaging, the benefits of enteric coating, and more.
In the coming months the combined company will work with its customer-facing teams to communicate its newly expanded product and service offerings to both existing and prospective customers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.